Becton Dickinson and Company (BDX)vsNyxoah (NYXH)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
NYXH
Nyxoah
$3.17
-0.63%
HEALTHCARE · Cap: $137.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 388692% more annual revenue ($21.92B vs $5.64M). BDX leads profitability with a 8.0% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
NYXH
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 55.8% year-over-year
Reasonable price relative to book value
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : NYXH
The strongest argument for NYXH centers on Revenue Growth, Price/Book. Revenue growth of 55.8% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH carries more volatility with a beta of 0.62 — expect wider price swings.
NYXH is growing revenue faster at 55.8% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is a pioneering medical technology firm specializing in the treatment of obstructive sleep apnea (OSA) through its innovative Genio system, which employs a minimally invasive hypoglossal nerve stimulation technique. The company is dedicated to enhancing patient outcomes and quality of life for those affected by OSA, backed by a strong commitment to clinical validation and research excellence. Nyxoah's strategic emphasis on technology advancement, complemented by partnerships and extensive studies, not only positions it to address significant unmet needs in the sleep medicine market but also underscores its potential for sustainable growth and transformative contributions to the healthcare industry.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?